Duchenne muscular dystrophy (DMD) is a genetic disease characterized by rapidly progressing weakness and degeneration of the skeletal muscles. This study presents a modeling approach using MR biomarkers to characterize disease progression in individuals with DMD receiving deflazacort, prednisone/prednisolone, or no corticosteroid treatment. The findings from a sample of convenience compiled from the ImagingDMD study demonstrate that 1) corticosteroid treatment slows DMD disease progression, with deflazacort slowing progression to a greater extent than prednisone/prednisolone, and 2) the slow-progressing muscles in DMD are more sensitive to treatment effects, and hence, could be better candidates to assess therapeutic response in clinical trials.
This abstract and the presentation materials are available to members only; a login is required.